CHEMO-FREE TRIPLET COMBINATION OF TGR-1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL

Authors :: Nathan Fowler
Jan A. Burger
M.T. Schreeder
Peter Sportelli
Michael S. Weiss
William G. Wierda
L. J. Nastoupil
Jonathon B. Cohen
M. Purdom
Susan O'Brien
Hari P. Miskin
Tanya Siddiqi
Christopher R. Flowers
Julie M. Vose
Matthew A. Lunning
Source :: Hematological Oncology. 35:112-113
Publication Year :: 2017
Publisher :: Wiley, 2017.

Subjects :: Cancer Research
business.industry
Hematology
General Medicine
030204 cardiovascular system & hematology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Oncology
chemistry
030220 oncology & carcinogenesis
Ibrutinib
Cancer research
Medicine
In patient
business

Tools